

Docket No: 290.0053 0101  
(US Nat'l Stage)

**DECLARATION**

We, Harry MORRISON, Elton MENON, Devanesan LOGANATHAN, Taj MOHAMMAD, Maribel Coromoto NAVARRO Acosta, and Mark A. BILLADEAU, declare that: (1) our respective citizenships and residence/mailling addresses are indicated below; (2) we have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein. (3) we believe that we are the original, first, and joint inventors of the subject matter in

**PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS**

U.S. National Stage Patent of International

Patent Application Serial No.: PCT/US 2003/024096; filed 01 August 2003

described and claimed therein and for which a patent is sought; and (4) we hereby acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability as defined in Title 37, Code of Federal Regulations, § 1.56.\*

We hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate listed below, or § 365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:

- a. ☒ no such applications have been filed.  
b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119(a)-(d), § 365(a), and/or § 365(b)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

ALL FOREIGN APPLICATIONS, IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

\* Title 37, Code of Federal Regulations, § 1.56 is reproduced on the attached page.

**BEST AVAILABLE COPY**

**Declaration**

Page 2 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024006)

Filing Date: Even Date Herewith

Title: **PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS**

We hereby claim the benefit under Title 35, United States Code §119(c) of any United States provisional application(s) listed below.

- a. ☐ no such applications have been filed.  
b. ☒ such applications have been filed as follows:

PROVISIONAL APPLICATION(S), IF ANY, UNDER 35 USC §119(c)	
APPLICATION NUMBER	DATE OF FILING (day, month, year)
60/400,262	01 August 2002

We hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

- a. ☒ no such applications have been filed.  
b. ☐ such applications have been filed as follows:

APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FROM : ORGANIC CHEMISTRY

FAX NO. : 765-496-2592

Feb. 18 2005 04:43PM

**Declaration**


Page 3 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024094)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

180  
  
Name: Harry MORRISON  
Citizenship: US  
Residence: 2844 Henderson Avenue  
West Lafayette, IN 47906  
US  
Mailing Address: same as residence IN  
(If different than Residence)

2/18/05  
Date

Name: Elton MENON  
Address: 3000 Kent Avenue  
West Lafayette, IN 47906  
Citizenship: US  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: Devanesan LOCANATHAN  
Address: 560 Oval Drive  
West Lafayette, IN 47907  
US  
Citizenship: Sri Lanka  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: Taj MOHAMMAD  
Address: 2224 Sandpiper Ct. So.  
West Lafayette, IN 47906-6511  
US  
Citizenship: US  
Mailing Address: same as residence  
(If different than Residence)

Date

**Declaration**

Page 3 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/RIS 2003/02-4096)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

Name: Harry MORRISON

Date

Citizenship: USResidence: 2844 Henderson Avenue  
West Lafayette, IN 47906,  
USMailing Address: same as residence  
(If different than Residence)Name: Elton MENON

Date

Address: 3000 Kent Avenue 4075 FOX HOLLOW CT  
West Lafayette, IN 47906 MASON, OH 45040 USCitizenship: US BRAZILMailing Address: same as residence  
(If different than Residence)Name: Devanesan LOGANATHAN

Date

Address: 560 Oval Drive  
West Lafayette, IN 47907  
USCitizenship: Sri LankaMailing Address: same as residence  
(If different than Residence)Name: Taj MOHAMMAD

Date

Address: 2224 Sandpiper Ct. So.  
West Lafayette, IN 47906-6511  
USCitizenship: USMailing Address: same as residence  
(If different than Residence)

FEB-19-2005 12:46

P.03/05

**Declaration**

Page 3 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024096)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

Name: **Harry MORRISON**  
Citizenship: **US**  
Residence: **2844 Henderson Avenue**  
**West Lafayette, IN 47906,**  
**US**  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: **Eitan MENON**  
Address: **3000 Kent Avenue**  
**West Lafayette, IN 47906**  
Citizenship: **US**  
Mailing Address: same as residence  
(If different than Residence)

Date

*D. Loganathan*  
Name: **Devanesan LOGANATHAN**  
Address: **560 Oval Drive**  
**West Lafayette, IN 47907**  
**US**  
Citizenship: **Sri Lanka** *IN*  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: **Taj MOHAMMAD**  
Address: **2224 Sandpiper Ct. So.**  
**West Lafayette, IN 47906-6511**  
**US**  
Citizenship: **US**  
Mailing Address: same as residence  
(If different than Residence)

Date

02/21/2005 17:50 7654648184

TAJ MOHAMMAD

Declaration

Page 3 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024096)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification, claims, and Declaration, on the date indicated below.

Name: Harry MORRISON  
Citizenship: US  
Residence: 2844 Henderson Avenue  
West Lafayette, IN 47906,  
US  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: Elton MENON  
Address: 3000 Keat Avenue  
West Lafayette, IN 47906  
Citizenship: US  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: Devanesan LOGANATHAN  
Address: 560 Oval Drive  
West Lafayette, IN 47907  
US  
Citizenship: Sri Lanka  
Mailing Address: same as residence  
(If different than Residence)

Date

Name: TAJ MOHAMMAD  
Address: 2224 Sandpiper Ct. So.  
West Lafayette, IN 47906-6511  
US  
Citizenship: US  
Mailing Address: same as residence  
(If different than Residence)

Date

FROM :

PHONE NO. :

Dec. 25 2004 02:30PM PS


**Declaration**

Page 4 of 5

Serial No. Unsigned (U.S. Nat'l Stage of PCT/AIS 2103/02-0006)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

  
Name: Maribel Coromoto NAVARRO Acosta  
Address: San Antonio de los Altos  
Urbanizacion San Juan Casa No. 20P  
Miranda Venezuela  
Citizenship: Venezuela  
Mailing Address: same as residence  
(If different than Residence)

JEX

2-24-2005

Date

Name: Mark A. BILLADEAU  
Address: 826 Valley Road  
Knoxville, MD 21758  
US  
Citizenship: US  
Mailing Address: same as residence  
(If different than Residence)

Date

**Declaration**

Page 4 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024096)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS

Name: **Maribel Coromoto NAVARRO Acosta**  
Address: San Antonio de los Altos  
Urbanizacion San Juan Casa No. 20P  
Miranda Venezuela  
Citizenship: Venezuela  
Mailing Address: same as residence  
(If different than Residence)

Date

6000 *Mark A. Billadeau*  
Name: **Mark A. BILLADEAU**  
Address: 826 Valley Road  
Knoxville, MD 21758  
US  
Citizenship: US MD  
Mailing Address: same as residence  
(If different than Residence)

*Feb 24, 2005*  
Date



**Declaration**

Page 5 of 5

Serial No. Unassigned (U.S. Nat'l Stage of PCT/US 2003/024066)

Filing Date: Even Date Herewith

Title: PHOTOACTIVATED ANTI-VIRAL AND ANTI-CANCER AGENTS**§ 1.56 Duty to disclose information material to patentability.**

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
  - (i) Opposing an argument of unpatentability relied on by the Office, or
  - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

(e) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**